vs
Side-by-side financial comparison of AC Immune SA (ACIU) and Sanofi (SNY). Click either name above to swap in a different company.
AC Immune SA is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics and diagnostic solutions for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and rare tauopathies. It operates globally, partners with leading pharmaceutical enterprises, and prioritizes addressing unmet medical needs in neurological care segments.
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of th...
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $1.4M | — | ||
| Q2 24 | $755.7K | — | ||
| Q3 22 | $4.3M | — |
| Q2 25 | $-23.3M | — | ||
| Q2 24 | $-25.0M | — | ||
| Q3 22 | $-14.9M | — |
| Q2 25 | -1484.5% | — | ||
| Q2 24 | -3051.1% | — | ||
| Q3 22 | -342.2% | — |
| Q2 25 | -1622.4% | — | ||
| Q2 24 | -3313.0% | — | ||
| Q3 22 | -343.6% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
